Revolution Medicines rises after FDA approves pancreatic cancer drug

Revolution Medicines

26/08/2026 15:59

** Shares of biotech firm Revolution Medicines RVMD.O rise 1% to $213.37
** Co says the U.S. FDA approved Rasonque for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer
** Says the once-daily pill is the first approved therapy in its class for the disease
** FDA says patients treated with Rasonque lived a median 13.2 months versus 6.7 months with standard chemotherapy in a 500-patient study
** Approval came about 6.5 months ahead of the FDA's review deadline
** Drug received breakthrough therapy, orphan drug and priority review designations before approval
** Including session's move, stock up ~165% YTD
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))